Cleared Traditional

K030234 - COZART EIA COCAINE ORAL FLIUD KIT

K030234 is an FDA 510(k) clearance for COZART EIA COCAINE ORAL FLIUD KIT, manufactured by Cozart Bioscience , Ltd.. The device is a Class 2 Toxicology device with product code DIO cleared through the Traditional 510(k) pathway after a 95-day FDA review.

K030234 · Cozart Bioscience , Ltd. · Toxicology device
Download Printable Device Report (PDF) Official FDA 510(k) Summary (PDF)
Optimized for regulatory review, auditing and printing
Apr 2003
Decision
95d
Days
Class 2
Risk

K030234 is an FDA 510(k) clearance for the COZART EIA COCAINE ORAL FLIUD KIT. Classified as Enzyme Immunoassay, Cocaine And Cocaine Metabolites (product code DIO), Class II - Special Controls.

Submitted by Cozart Bioscience , Ltd. (Abingdon,Oxfordshire, GB). The FDA issued a Cleared decision on April 28, 2003 after a review of 95 days - within the typical 510(k) review window.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3250 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Toxicology review framework, consistent with the majority of Class II 510(k) submissions.

FDA 510(k) Submission Details - K030234

510(k) Number K030234 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 23, 2003
Decision Date April 28, 2003
Days to Decision 95 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
8d slower than avg
Panel avg: 87d · This submission: 95d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DIO Device Classification - Class 2, Special Controls

Product Code DIO Enzyme Immunoassay, Cocaine And Cocaine Metabolites
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3250
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - DIO Enzyme Immunoassay, Cocaine And Cocaine Metabolites

All 144
Devices cleared under the same product code (DIO) and FDA review panel - the closest regulatory comparables to K030234.
AML HAIRCHECK-DT (COCAINE)
K023626 · Quest Diagnostics, Inc. · Sep 2003
TOXCUP DRUG SCREEN CUP AMP/COC/MET/OPI/PCP/THC
K032057 · Branan Medical Corp. · Aug 2003
EMIT II PLUS COCAINE METABOLITE ASSAY
K031512 · Dade Behring, Inc. · Jul 2003
QUICKTOX MULTIPLE DRUG DIPCARD
K023489 · Branan Medical Corp. · Dec 2002
ONLINE DAT II COCAINE II
K023281 · Roche Diagnostics Corp. · Dec 2002
COBAS INTEGRA ONLINE DAT II COCAINE II
K023296 · Roche Diagnostics Corp. · Nov 2002
K030234 · COZART EIA COCAINE ORAL FLIUD KIT
Download PDF FDA Summary Cozart Bioscience , L…